Combination therapy with flupirtine and opioid: studies in rat pain models.

OBJECTIVES Flupirtine is an established clinical analgesic for mild to moderate musculoskeletal pain states. It has recently been shown to be a KCNQ2-3 potassium channel opener. These experiments were performed to see if this property could be useful in treating pain states characterized by central sensitization with the drug either given alone or in combination with morphine. DESIGN Experiments were performed in rats in an observer-blinded fashion with vehicle controls. Nonsedating doses of flupirtine, morphine, and combinations containing both drugs were defined using the rotarod test and open-field activity monitoring. Dose-response relationships were determined for nonsedating doses of both drugs given alone and together in combination in causing antinociception in two nociception paradigms: carrageenan paw inflammation and streptozotocin-induced diabetic neuropathy. RESULTS Flupirtine and morphine, when given alone at the highest nonsedating doses, caused slight to moderate antinociception in both paradigms. Flupirtine also caused significant increases in morphine antinociception in both models. In carrageenan paw inflammation, complete reversal of carrageenan-induced hyperalgesia was caused by 10 mg/kg flupirtine in combination with 0.4 mg/kg morphine. These doses of the two drugs were ineffective when given alone, but the combination caused complete antinociception in this model of inflammatory pain. In the diabetic neuropathy model, morphine 3.2 mg/kg given alone caused no significant antinociception. However, a lower dose of morphine (1.6 mg/kg shown to be ineffective when it was given alone) given in combination with flupirtine 10 mg/kg caused highly significant antinociceptive effects causing complete reversal of hyperalgesia caused by diabetic neuropathy (P < 0.001, one-way analysis of variance). This combination of drugs was not sedating. CONCLUSIONS Flupirtine increases morphine antinociception without causing an increase in sedation. Flupirtine should be investigated as an adjunct analgesic with opioids for the management of patients with pain states involving central sensitization.

[1]  K. Pavelka.  Symptomatic treatment of osteoarthritis: paracetamol or NSAIDs? , 2004, International journal of clinical practice. Supplement.

[2]  M. Schurr,et al.  Complex regional pain syndrome as a complication of a chemical burn to the foot. , 2004, The Journal of burn care & rehabilitation.

[3]  Maurizio Taglialatela,et al.  M Channels Containing KCNQ2 Subunits Modulate Norepinephrine, Aspartate, and GABA Release from Hippocampal Nerve Terminals , 2004, The Journal of Neuroscience.

[4]  V. Gribkoff.  The therapeutic potential of neuronal KCNQ channel modulators , 2003, Expert opinion on therapeutic targets.

[5]  A. Gordon,et al.  Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy , 2003, Pain.

[6]  A. Dickenson,et al.  KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy , 2003, The Journal of Neuroscience.

[7]  M. Blanar,et al.  Functional Expression of Two KvLQT1-related Potassium Channels Responsible for an Inherited Idiopathic Epilepsy* , 1998, The Journal of Biological Chemistry.

[8]  M. Devor,et al.  Cases 1A and 1B. 1995 intravenous lidocaine infusion for chronic pain therapy. , 1996, Israel journal of medical sciences.

[9]  R. Portenoy.  Adjuvant analgesic agents. , 1996, Hematology/oncology clinics of North America.

[10]  B. Galer.  Neuropathic pain of peripheral origin , 1995, Neurology.

[11]  F. Block,et al.  N-methyl-D-aspartate and alpha 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats. , 1995, European journal of pharmacology.

[12]  N. Osborne,et al.  Immunohistochemical evidence for flupirtine acting as an antagonist on theN-methyl-d-aspartate and homocysteic acid-induced release of GABA in the rabbit retina , 1994, Brain Research.

[13]  F. Block,et al.  N-methyl-D-aspartate (NMDA)-mediated muscle relaxant action of flupirtine in rats. , 1994, Neuroreport.

[14]  A. Eschalier,et al.  Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics , 1994, Pain.

[15]  A. Eschalier,et al.  Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain , 1993, Pain.

[16]  M. Max.  U.S. Government disseminates acute pain treatment guidelines: will they make a difference? , 1992, Pain.

[17]  B. Meyerson,et al.  Genuine resistance to opioids — fact or fiction? , 1991, Pain.

[18]  R. Portenoy,et al.  Response to the letters to the editor by Dr. Du Pen and Ms. A. Williams and by Drs. Arnér and Meyerson , 1991, Pain.

[19]  S. Cartmell,et al.  A revised rotarod procedure for measuring the effect of antinociceptive drugs on motor function in the rat. , 1991, Journal of pharmacological methods.

[20]  K. E. Moore,et al.  Noradrenergic innervation to the VMN or MPN is not necessary for lordosis , 1991, Pharmacology Biochemistry and Behavior.

[21]  R. Portenoy,et al.  The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions , 1990, Pain.

[22]  K. Brøsen,et al.  The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms , 1990, Pain.

[23]  M. Max.  Towards physiologically based treatment of patients with neuropathic pain , 1990, Pain.

[24]  I. Jurna,et al.  Flupirtine depresses nociceptive activity evoked in rat thalamus. , 1988, European journal of pharmacology.

[25]  B. Meyerson,et al.  Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain , 1988, Pain.

[26]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[27]  D. A. Brown,et al.  Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone , 1980, Nature.

[28]  R. Lo,et al.  A method for measurement of analgesic activity on inflamed tissue. , 1957 .

[29]  C. Parsons,et al.  Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels , 1999, Journal of Neural Transmission.

[30]  N. Marrion,et al.  Control of M-current. , 1997, Annual review of physiology.

[31]  A. Fitton,et al.  Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. , 1993, Drugs.

[32]  L. O. Randall,et al.  A method for measurement of analgesic activity on inflamed tissue. , 1957, Archives internationales de pharmacodynamie et de therapie.

[33]  C. Parsons,et al.  Flupirtine shows functional NMDA receptor antagonism by enhancing Mg21 block via activation of voltage independent potassium channels Rapid Communication , 2022 .